Johnson & Johnson, of New Brunswick, N.J., said new data for its Xarelto (rivaroxaban), published in the October issue of Thrombosis Research, show reduced risk of recurrent venous thromboembolism in morbidly obese patients, with effectiveness and safety similar to warfarin.